Table Graph
      published meta-analysis   sensitivity analysis   studies

regdanvimab (Regkirona- CT-P59-Celltrion) in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCT-P59 3.2 part 2, 2021 0.50 [0.05; 5.54] 0.50[0.05; 5.54]CT-P59 3.2 part 2, 202110%1,315NAnot evaluable hospitalization or deathdetailed resultsCT-P59 3.2 part 1, 2021 0.48 [0.19; 1.25] CT-P59 3.2 part 2, 2021 0.29 [0.16; 0.51] 0.33[0.20; 0.53]CT-P59 3.2 part 1, 2021, CT-P59 3.2 part 2, 202120%1,622NAnot evaluable clinical improvement (time to event analysis only)detailed resultsCT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74] 1.50[1.30; 1.74]CT-P59 3.2 part 2, 202110%1,315NAnot evaluable Recovery (time to event analysis only)detailed resultsCT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74] 1.50[1.30; 1.74]CT-P59 3.2 part 2, 202110%1,315NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-23 14:36 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 690 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons